Want to see TXG full AI Analyst Report?
TXG Stock Chart & Stats
$46.27
-$0.99(-2.14%)
At close: 4:00 PM EDT
$46.27
-$0.99(-2.14%)
Day’s Range― - ―
52-Week Range$11.16 - $64.53
Previous CloseN/A
Volume477.04K
Average Volume (3M)3.24M
Market Cap
$8.10B
Enterprise Value$4.51K
Total Cash (Recent Filing)$552.03M
Total Debt (Recent Filing)$78.80M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 04, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding120,212,296
10 Day Avg. Volume3,169,027
30 Day Avg. Volume3,237,149
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$50.36Price Target Upside8.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$620.12M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthConsumables provide recurring revenue after instrument placement. Continued growth in reaction volumes and spatial usage indicates expanding platform utilization and can improve revenue durability as customers run more experiments.
Strong Liquidity And Cash GenerationPositive operating and free cash flow, combined with substantial liquidity and low leverage, gives 10x Genomics flexibility to fund product development, absorb demand volatility, and pursue growth without near-term financing dependence.
Atera Demand And Platform ExpansionStrong early Atera orders validate demand for a new spatial whole-transcriptome platform. Its potential for higher consumable pull-through, alongside multi-omics expansion, could strengthen the installed-base ecosystem over time.
Bears Say
Profitability Remains UnprovenDespite improved gross margins and narrower historical losses, the company has not yet established sustained operating profitability. Continued losses could constrain reinvestment capacity and make results more dependent on future revenue growth.
Instrument Sales And Shipment Capacity WeaknessInstrument placements expand the future consumables base, so the sharp decline and manufacturing limits weaken near-term platform expansion. Delayed Atera shipments also postpone revenue recognition and the anticipated recurring pull-through.
Cash-flow Momentum Is SlowingCurrent cash generation is a strength, but negative free-cash-flow growth suggests the recent improvement may be normalizing. If operating losses persist or investment rises for Atera and multi-omics, cash conversion could weaken.
TXG FAQ
What was 10X Genomics’s price range in the past 12 months?
10X Genomics lowest stock price was $11.16 and its highest was $64.53 in the past 12 months.
What is 10X Genomics’s market cap?
10X Genomics’s market cap is $8.10B.
When is 10X Genomics’s upcoming earnings report date?
10X Genomics’s upcoming earnings report date is Nov 04, 2026 which is in 74 days.
How were 10X Genomics’s earnings last quarter?
10X Genomics released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.103.
Is 10X Genomics overvalued?
According to Wall Street analysts 10X Genomics’s price is currently Undervalued.
Does 10X Genomics pay dividends?
10X Genomics does not currently pay dividends.
What is 10X Genomics’s EPS estimate?
10X Genomics’s EPS estimate is -0.27.
How many shares outstanding does 10X Genomics have?
10X Genomics has 120,212,296 shares outstanding.
What happened to 10X Genomics’s price movement after its last earnings report?
10X Genomics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went up 14.101%.
Which hedge fund is a major shareholder of 10X Genomics?
Currently, no hedge funds are holding shares in TXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$50.36 (8.85% Upside)
$50.36 (8.85% Upside)
Blogger Sentiment
Neutral
TXG Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
236.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.11%
Trailing 12-Months
Company Description
10X Genomics
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
TXG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a constructive mix of operational positives — notably Atera's outsized early demand, solid consumables growth (+7% total; spatial +16%), gross margin expansion to 74%, and a raised full‑year revenue guide — while flagging near‑term cadence challenges driven by instrument revenue declines (‑47%) and manufacturing/shipment constraints for Atera that produce an expected Q3 sequential dip. The business shows healthy underlying consumable momentum and strategic positioning (M&A, multi‑omics, AI tailwinds), but short‑term instrument timing and APAC comparatives introduce visibility headwinds.View all TXG earnings summariesTXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China

TXG Stock 12 Month Forecast
Average Price Target
$50.36
▲(8.85% Upside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―
Ownership Overview
2.39% Insiders
25.85% Mutual Funds
29.08% Other Institutional Investors
18.80% Public Companies and
Individual Investors













